Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results
- 作者: Tsaplina N.1, Valiev T.1, Kirgizov K.1, Varfolomeeva S.1
-
隶属关系:
- Blokhin National Medical Research Center of Oncology
- 期: 卷 25, 编号 1 (2023)
- 页面: 78-81
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132798
- DOI: https://doi.org/10.26442/18151434.2023.1.202121
- ID: 132798
如何引用文章
全文:
详细
Background. Introduction a targeted drugs in a real clinical practice bring a vast improvement of prognosis in patients with relapsed and refractory (r/r) Hodgkin lymphoma (HL). But it is necessary to increase the experience in anti-CD30 monoclonal antibodies in combination with second-line chemotherapy in pediatric oncology/hematology.
Aim. To estimate the effectiveness of chemoimmunotherapy (ViGePD+BV scheme) in pediatric patients with r/r classical HL (cHL).
Materials and methods. From January 2018 to October 2022, 15 patients with r/r cHL received scheme ViGePD+BV. Programmed treatment included autologous stem cell transplantation (auto-SCT) in 11 (73%) patients. The potency assignment of antitumour treatment was performed with positron emission tomography/computed tomogtaphy (PET-CT).
Results. Complete metabolic response (PET-negative status) was achieved in all 15 (100%) patients after 4 inductive courses by ViGePD+BV scheme; 4-year relapse-free survival was 90.9±8.7%.
Conclusion. Our preliminary data of a pilot protocol of study a chemoimmunotherapy effectiveness for r/r cHL with brentuximab vedotin show a high potency of ViGePD+BV scheme in patients with r/r HL.
作者简介
Natalia Tsaplina
Blokhin National Medical Research Center of Oncology
Email: natalia_kulichkina@mail.ru
ORCID iD: 0000-0002-3511-357X
Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology
俄罗斯联邦, MoscowTimur Valiev
Blokhin National Medical Research Center of Oncology
编辑信件的主要联系方式.
Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-1469-2365
D. Sci. (Med.), Blokhin National Medical Research Center of Oncology
俄罗斯联邦, MoscowKirill Kirgizov
Blokhin National Medical Research Center of Oncology
Email: k.kirgizov@ronc.ru
ORCID iD: 0000-0002-2945-284X
Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology
俄罗斯联邦, MoscowSvetlana Varfolomeeva
Blokhin National Medical Research Center of Oncology
Email: s.varfolomeeva@ronc.ru
ORCID iD: 0000-0001-6131-1783
D. Sci. (Med.), Prof., Blokhin National Medical Research Center of Oncology
俄罗斯联邦, Moscow参考
- Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 2018;131(15):1679-88.
- Hematologic malignancies: Hodgkin lymphoma. Eds A Engert, A Younes. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg. Springer, 2015. doi: 10.1007/978-3-319-12505-3
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-5.
- Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065-71.
- NCCN (2019). NCCN clinical practice guidelines in oncology (NCCN guidelines®) for Hodgkin lymphoma V.2.2019. Available at: https://www.nccn.org/ professionals/physician_gls/pdf/hodgkins.pdf. Accessed: 01.10.2019.
- Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv19-29.
- Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-40.
- Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-42.
- Hagenbeek A, Zijlstra JM, Plattel WJ, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Blood. 2018;132(Suppl. 1):2923.
- Garcia-Sanz R, Sureda A, De La Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019;30(4):612-20.
- Stamatoullas A, Ghesquieres H, Clement filliatre L, et al. Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study. Blood. 2019;134(Suppl. 1):132.
- Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428-39.
- Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med. 2021;9(12):1037. doi: 10.21037/atm-20-6833
- Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-39. doi: 10.1200/JCO.2017.76.0793